Page 424 - Read Online

Page 20 of 22 Droste et al. J Cancer Metastasis Treat 2023;9:2 https://dx.doi.org/10.20517/2394-4722.2022.94

DOI PubMed PMC
79. Jeong H, Jeong JH, Kim JE, Ahn JH, Jung KH, Kim SB. Comparison of the effectiveness and clinical outcome of everolimus
followed by CDK4/6 inhibitors with the opposite treatment sequence in hormone receptor-positive, HER2-negative metastatic breast
cancer. Cancer Res Treat 2022;54:469-77. DOI PubMed PMC
80. Wolff AC, Lazar AA, Bondarenko I, et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-
line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013;31:195-202.
DOI
81. Vinayak S, Carlson RW. mTOR inhibitors in the treatment of breast cancer. Oncology 2013;27:38-44. PubMed
82. Gökmen-Polar Y, Liu Y, Toroni RA, et al. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral
antitumor activity in human breast cancer xenograft models. Breast Cancer Res Treat 2012;136:673-82. DOI PubMed
83. Zeng Z, Wang RY, Qiu YH, et al. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in
AML and AML stem/ progenitor cells. Oncotarget 2016;7:55083-97. DOI PubMed PMC
84. Zhang X, Wang X, Xu T, Zhong S, Shen Z. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the
treatment of malignant pheochromocytoma. Tumour Biol 2015;36:5273-81. DOI PubMed
85. Zou Z, Chen J, Yang J, Bai X. Targeted inhibition of rictor/mTORC2 in cancer treatment: a new era after rapamycin. Curr Cancer
Drug Targets 2016;16:288-304. DOI PubMed
86. García-Sáenz JÁ, Martínez-Jáñez N, Cubedo R, et al. Sapanisertib plus fulvestrant in postmenopausal women with estrogen receptor-
positive/HER2-negative advanced breast cancer after progression on aromatase inhibitor. Clin Cancer Res 2022;28:1107-16. DOI
PubMed PMC
87. Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70. DOI PubMed PMC
88. Goncalves MD, Hopkins BD, Cantley LC. Phosphatidylinositol 3-kinase, growth disorders, and cancer. N Engl J Med
2018;379:2052-62. DOI PubMed
89. Bosch A, Li Z, Bergamaschi A, et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone
receptor-positive breast cancer. Sci Transl Med 2015;7:283ra51. DOI
90. Dent S, Cortés J, Im YH, et al. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive,
PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Ann Oncol 2021;32:197-207. DOI PubMed PMC
91. Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-
positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
Oncol 2017;18:904-16. DOI PubMed PMC
92. Krop IE, Mayer IA, Ganju V, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic
breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2016;17:811-21. DOI PubMed
PMC
93. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J
Med 2019;380:1929-40. DOI
94. Juric D, Ciruelos E, Rubovszky G, et al. Abstract GS3-08: alpelisib + fulvestrant for advanced breast cancer: subgroup analyses from
the phase III SOLAR-1 trial. Cancer Res 2019;79:GS3-08. DOI
95. André F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal
growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol 2021;32:208-17.
DOI PubMed
96. Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast
cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol
2021;22:489-98. DOI PubMed
97. Turner S, Chia S, Kanakamedala H, et al. Effectiveness of alpelisib + fulvestrant compared with real-world standard treatment among
patients with HR+, HER2-, PIK3CA-mutated breast cancer. Oncologist 2021;26:e1133-42. DOI PubMed PMC
98. Hopkins BD, Pauli C, Du X, et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 2018;560:499-
503. DOI
99. Michaloglou C, Crafter C, Siersbaek R, et al. Combined inhibition of mTOR and CDK4/6 is required for optimal blockade of E2F
function and long-term growth inhibition in estrogen receptor-positive breast cancer. Mol Cancer Ther 2018;17:908-20. DOI
PubMed PMC
100. Vora SR, Juric D, Kim N, et al. CDK4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell
2014;26:136-49. DOI
101. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008;133:403-14. DOI PubMed
102. Bertucci F, Ng CKY, Patsouris A, et al. Genomic characterization of metastatic breast cancers. Nature 2019;569:560-4. DOI
103. Carbognin L, Miglietta F, Paris I, Dieci MV. Prognostic and predictive implications of PTEN in breast cancer: unfulfilled promises
but intriguing perspectives. Cancers 2019;11:1401. DOI PubMed PMC
104. Costa C, Wang Y, Ly A, et al. PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast cancer. Cancer
Discov 2020;10:72-85. DOI PubMed
105. Juric D, Castel P, Griffith M, et al. Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor. Nature 2015;518:240-4.
DOI PubMed PMC